search
Back to results

Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG

Primary Purpose

Ventricular Arrhythmias

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Implantable Cardioverter Defibrillator
Sponsored by
Medtronic Cardiac Rhythm and Heart Failure
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ventricular Arrhythmias focused on measuring Implantable Cardioverter Defibrillator, Anti-tachycardia pacing (ATP)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects with failure but no symptoms (NYHA Class I) or subjects with mild heart failure that only sometimes interferes with daily activities (NYHA Class II) Subjects who have, or are risk of having, a heart beat that is too fast and his/her doctor has determined he/she needs an implantable cardioverter defibrillator (ICD) Subjects who have, or are at risk of developing, rapid beats in the upper chambers of the heart (atrial tachyarrhythmias) Exclusion Criteria: Subjects with rapid heart beats in their ventricles (lower chambers of the heart) associated only with reversible causes Subjects with mechanical tricuspid heart valves (A structure in the heart, located between the right atrium and right ventricle, which allows blood to flow down from the atrium into the ventricle.)

Sites / Locations

Outcomes

Primary Outcome Measures

Safety and efficacy at three months.

Secondary Outcome Measures

To evaluate how well the device distinguished between arrhythmias originating in the atrium versus those that originate in the ventricle.
To evaluate how well the anti-tachycardia pacing function works.
To observe the overall performance of the device system.

Full Information

First Posted
January 4, 2006
Last Updated
October 11, 2006
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
search

1. Study Identification

Unique Protocol Identification Number
NCT00273195
Brief Title
Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG
Official Title
Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG
Study Type
Interventional

2. Study Status

Record Verification Date
October 2006
Overall Recruitment Status
Completed
Study Start Date
April 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Medtronic Cardiac Rhythm and Heart Failure

4. Oversight

5. Study Description

Brief Summary
People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD). An ICD is implanted surgically just under the skin in the upper chest area and it sends a strong electrical impulse, or shock, to the heart to return it to a normal rhythm. The purpose of this study was to evaluate the safety and efficacy of the EnTrust ICD device. A feature of this device allows it to send small, painless electrical impulses (Anti-tachycardia pacing or ATP) to the heart instead of shocking it out of a rhythm that is too fast. Stopping a dangerous heart rhythm this way does not cause any pain whereas a shock to the heart can feel like a punch in the chest. This device also allows the heart to beat on its own when it can and helping it (by pacing, or sending it electrical signals) when it needs help. This feature is important because previously studies have shown that pacing the heart too often can increase the risk for heart failure or for atrial fibrillation (having too rapid of heart beats in the atrium). This study is now complete and the device has since been approved by the FDA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventricular Arrhythmias
Keywords
Implantable Cardioverter Defibrillator, Anti-tachycardia pacing (ATP)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
500 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Implantable Cardioverter Defibrillator
Primary Outcome Measure Information:
Title
Safety and efficacy at three months.
Secondary Outcome Measure Information:
Title
To evaluate how well the device distinguished between arrhythmias originating in the atrium versus those that originate in the ventricle.
Title
To evaluate how well the anti-tachycardia pacing function works.
Title
To observe the overall performance of the device system.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects with failure but no symptoms (NYHA Class I) or subjects with mild heart failure that only sometimes interferes with daily activities (NYHA Class II) Subjects who have, or are risk of having, a heart beat that is too fast and his/her doctor has determined he/she needs an implantable cardioverter defibrillator (ICD) Subjects who have, or are at risk of developing, rapid beats in the upper chambers of the heart (atrial tachyarrhythmias) Exclusion Criteria: Subjects with rapid heart beats in their ventricles (lower chambers of the heart) associated only with reversible causes Subjects with mechanical tricuspid heart valves (A structure in the heart, located between the right atrium and right ventricle, which allows blood to flow down from the atrium into the ventricle.)
Facility Information:
City
Little Rock
State/Province
Arkansas
Country
United States
City
Glendale
State/Province
California
Country
United States
City
Inglewood
State/Province
California
Country
United States
City
Atlantis
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Macon
State/Province
Georgia
Country
United States
City
Ft. Wayne
State/Province
Indiana
Country
United States
City
Davenport
State/Province
Iowa
Country
United States
City
Des Moines
State/Province
Iowa
Country
United States
City
Salisbury
State/Province
Maryland
Country
United States
City
Boston
State/Province
Massachusetts
Country
United States
City
Kansas City
State/Province
Missouri
Country
United States
City
St. Louis
State/Province
Missouri
Country
United States
City
Winston-Salem
State/Province
North Carolina
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Abington
State/Province
Pennsylvania
Country
United States
City
Lancaster
State/Province
Pennsylvania
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Amarillo
State/Province
Texas
Country
United States
City
Austin
State/Province
Texas
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Richmond
State/Province
Virginia
Country
United States
City
Morgantown
State/Province
West Virginia
Country
United States
City
Milwaukee
State/Province
Wisconsin
Country
United States
City
St. Poelten
Country
Austria
City
Steyr
Country
Austria
City
Calgary
State/Province
Alberta
Country
Canada
City
Vancouver
State/Province
British Columbia
Country
Canada
City
Kingston
State/Province
Ontario
Country
Canada
City
Toronto
State/Province
Ontario
Country
Canada
City
Montreal
State/Province
Quebec
Country
Canada
City
Sainte-Foy
State/Province
Quebec
Country
Canada
City
Copenhagen
Country
Denmark
City
Bonn
Country
Germany
City
Goettingen
Country
Germany
City
Heidelberg
Country
Germany
City
Kaiserslautern
Country
Germany
City
Muenchen
Country
Germany
City
Muenster
Country
Germany
City
Eindhoven
Country
Netherlands
City
Basel
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG

We'll reach out to this number within 24 hrs